Vaginal administration

NuvaRing is inserted directly into the vagina, which allows for low, steady and continuous dosing and results in stable serum concentrations of etonogestrel and ethinylestradiol.1 The delivery of hormones afforded by vaginal administration has been shown to be more consistent than delivery via the contraceptive patch and certain combined oral contraceptives.10

NuvaRing provides low, steady-state, continuous dosing. Adapted from van den Heuvel et al.10

NuvaRing provides low, steady-state, continuous dosing

 

 

Adverse events should be reported. Reporting forms and information can be found at www.yellowcard.gov.uk.
Adverse events should also be reported to MSD Drug Safety Department on 01707 363773

Organon

Expiry 10/11 - NUV.10.GB.27040.AV

© 2010 Copyright Organon Laboratories Limited. All rights reserved.

Terms and Conditions
Privacy Policy


© 2010 Organon Laboratories Ltd trading as MSD: Registered Address: Hertford Road, Hoddesdon, Hertfordshire, EN11 9BU.
A company registered in England and Wales. Company Registration Number: 820771